Hoth Therapeutics, Inc. Share Price & Technical Analysis
HOTH · $0.69 (+7.81%)
Healthcare / Biotechnology
$0.69
+7.81%
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to t…
Price chart
Seasonality
May has 0 positive and 3 negative years (last 5 years shown)
0% return in May, -6% avg return in past 3 year May month.
-41% return in 2026, -45% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -10% | 11% | -20% | -22% | 0% | – | – | – | – | – | – | – | -41% |
| 25 | 63% | -25% | 11% | -10% | -11% | 50% | 8% | -8% | 23% | -12% | -14% | -17% | 58% |
| 24 | 0% | -8% | 15% | -20% | 0% | -25% | -22% | 0% | 29% | 0% | -11% | -22% | -64% |
| 23 | -27% | -43% | -28% | -23% | -6% | 67% | -16% | -15% | -32% | -25% | -8% | 27% | -129% |
| 22 | -14% | 0% | 18% | -25% | -15% | -4% | 2% | 7% | -22% | -34% | -24% | 90% | -21% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. The company was incorporated in 2017 and is based in Hoboken, New Jersey.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$12.70M
P/E ratio
—
52W high
$2.12
52W low
$0.49
Volume
4,08,562
Beta
0.58
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Hoth Therapeutics, Inc. share price today?
- Hoth Therapeutics, Inc. (HOTH) last traded around $0.69 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does HOTH have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for HOTH. Download the app for real-time alerts.
- How can I analyze Hoth Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.